SAHA (Vorinostat)

SKU: orb1308090

Featured

Description

Vorinostat (SAHA) is a potent pan-HDAC inhibitor targeting HDAC1, 2, 3, 6, 7, and 11. It exhibits antitumor properties by inducing cell cycle arrest, differentiation, and apoptosis, making it a key tool for cancer research in both in vitro and in vivo experimental models.

Research Area

Cell Biology, Epigenetics & Chromatin, Stem Cell & Developmental Biology

Images & Validation

−

Key Properties

−

CAS Number	149647-78-9
MW	264.3
Purity	>98%
Formula	C₁₄H₂₀N₂O₃
SMILES	N(C(CCCCCCC(NO)=O)=O)C1=CC=CC=C1
Target	Protein deacetylase
Solubility	Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 2 mg/ml).

Bioactivity

−

Target IC50	Vorinostat cells:8.6 μM\|ASPC1 cells:3.09 μM\|4T1 cells:1.59 μM\|ACHN cells:2.08 μM\|A2780 cells:> 1000 nM\|HDAC3:20 nM (ID50)\|B16 cells:2.26 μM\|518A2 cells:0.9 μM\|A498 cells:25.08 μM\|A375 cells:2.68 μM\|AGS cells:4 μM\|HDAC:~10 nM (cell free)\|A431 cells:0.63 μM\|B16 F10 cells:11.36 μM\|HDAC1:10 nM (ID50)\|SW1353 cells:2.0 μM Read more...
In Vivo	METHODS: To detect anti-tumor activity in vivo, Vorinostat (50 mg/kg in HOP-β-CD) was administered intraperitoneally to Nude-Foxn1nu/nu mice bearing uterine sarcoma MES-SA five times per week for twenty-one days. RESULTS: A reduction in tumor growth of more than 50% was observed in the Vorinostat treatment group compared to the placebo group. METHODS: To study the effects in an animal model of true erythrocytosis (PV), Vorinostat (200 mg/kg in 50% PEG-400) was injected intraperitoneally into MxCre;Jak2V617F/+ mice five times per week for two weeks. RESULTS: Vorinostat treatment normalized peripheral blood counts and significantly reduced splenomegaly in Jak2V617F knockout mice.Vorinostat may have therapeutic potential for PV and other JAK2V617F-associated myeloproliferative tumors. Read more...
In Vitro	METHODS: Synovial sarcoma cells SW-982 and chondrosarcoma cells SW-1353 were treated with Vorinostat (0.5-15 μM) for 48 h, and cell viability was measured by MST assay. RESULTS: Vorinostat inhibited the proliferation of SW-982 and SW-1353 cells in a dose-dependent manner with IC50s of 8.6 μM and 2.0 μM, respectively. METHODS: Uterine sarcoma cells MES-SA were treated with Vorinostat (3 μM) for 24-72 h. The expression levels of target proteins were detected using Western Blot. RESULTS: There was no difference in the expression of HDAC1 throughout the treatment period, and HDAC2, 3 and 7 showed significant inhibition of expression by Vorinostat. Read more...
Cell Research	Cells were plated onto 100-mm tissue culture plates at a density of 2 × 10^6 for 48 h and then treated with SAHA or equal concentrations of the vehicle. For longer drug exposure times, medium with drug or vehicle were exchanged every 48 h. For wash-out experiments, cells were treated with SAHA daily for 60–72 h (drug and medium were exchanged at 48 h), then SAHA was washed out and replaced with 10% FCS containing DMEM . Read more...
Animal Research	Athymic Nude-Foxn1nu/nu mice were used in the present study. They were housed at 22°C at a constant light-dark cycle (12-h light, 12-h dark) and had free access to water and rodent chow (4-5% fat, 21% protein). Twelve weeks old male mice (n = 14) were anesthetized with Isofluran and 5 × 10^6 MES-SA cells were injected subcutaneously into the right flank of the animal. Mice from a control group received placebo containing 300 μl of empty HOP-β-CD (2-hydroxypropyl-β-cyclodextrin) vesicles. Another group of mice received vorinostat dissolved in HOP-β-CD at a concentration of 50 mg/kg/day. Both, empty vesicles and vorinostat were administered intraperitoneally, starting on the day 4 after the injection of MES-SA tumor cells. Mice body weight and tumor size (w2 × l × 0.52; measured by caliper) were estimated twice a week. All mice were treated for 21 days and afterward sacrificed by cervical dislocation. Each tumor was isolated as a whole and different tumor parameters (weight, volume, size, and macroscopic appearance) were determined. Finally, tumor slices were cryopreserved and formalin fixed (4%) for further analyses . Read more...

Storage & Handling

−

Storage	RT
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Vorinostat

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

5311 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

SAHA (Vorinostat) (orb1308090)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

CAS Number:	1613617-05-2
MW:	719.26
Formula:	C₃₃H₅₅ClN₄O₁₁

Purity:	>98% (HPLC)
CAS Number:	935881-37-1
MW:	312.36
Formula:	C₁₈H₂₀N₂O₃

Purity:	>98% (HPLC)
CAS Number:	1012054-59-9
MW:	434.4876
Formula:	C₂₄H₂₆N₄O₄

Purity:	>98% (HPLC)
CAS Number:	149647-78-9
MW:	264.3202
Formula:	C₁₄H₂₀N₂O₃

SAHA (Vorinostat)

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

SAHA chloroalkane T1 [orb1706077]

AR-42 [orb1222983]

CUDC-101 [orb1227156]

Vorinostat [orb1226185]

SAHA (Vorinostat) [orb3066694]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

SAHA (Vorinostat) (orb1308090)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors